On September 12, 2023 Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, reported an update on development of its PD1-Vaxx clinical drug candidate (Press release, Imugene, SEP 12, 2023, https://mcusercontent.com/e38c43331936a9627acb6427c/files/b84086de-66ea-1143-ed9d-b6751a178dfa/Imugene_PD1_Vaxx_Update.pdf [SID1234635074]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Imugene announces the grant of a new patent (number 2019-553504) by the Japanese Patent Office. The granted claims protect Imugene’s immunotherapeutic PD1-Vaxx, a first-in-class programmed death-1 (PD1) vaccine, currently in clinical development for non-small cell lung cancer (NSCLC).
The patent titled "HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF" will expire on 28 March 2038 and protects the composition of matter and method of treatment in cancer of Imugene’s PD1-Vaxx for the generation of a therapeutic antibody response against the PD1 checkpoint target.
Imugene’s PD1-Vaxx is a B-cell activating immunotherapy designed to treat tumours such as lung cancer by interfering with PD-1/PD-L1 binding and interaction and produce an anti-cancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies that are transforming the treatment of a range of cancers.
Last week marked 1000 days cancer free for a patient with late-stage NSCLC who was recruited and dosed in December 2020. This week Professor Michael Boyer M.D., MBBS, FRACP, PhD, Chris O’Brien Lifehouse Hospital will present a trial-in-progress poster in person at the IASLC 2023 World Conference on Lung Cancer (WCLC 2023) in Singapore. The poster presentation can be downloaded from Imugene’s website, View Source
Imugene MD & CEO Leslie Chong said: "Attaining the key Japanese patent, on top of gaining protection in the USA this year, is a very important milestone. Recruitment in the Phase 1 PD1-Vaxx trial, as monotherapy or in combination with atezolizumab in adults with NonSmall Cell Lung Cancer, has increased markedly recently with strong interest from new clinical sites to participate in this innovative study".